Amarantus BioScience Holdings, Inc. (AMBS) received a Notice of Allowance from the U.S. Patent and Trademark Office covering the use of 5HT1A in combination with 5HT1B agonists, including the clinical Phase 2b stage drug eltoprazine, to treat levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease (PD). The office issues such a…
News
University of Nebraska Medical Center and Longevity Biotech researchers demonstrated that LBT-3627, a novel drug candidate developed by the company, prevented nerve cell damage and protected dopamine-producing cells in a mouse model of Parkinson’s disease. The research paper, entitled “Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in…
International Stem Cell Corporation announced that its subsidiary, Cyto Therapeutics, has been given regulatory permission to start a Phase 1/2a dose escalation clinical trial of its neural stem cells (ISC-hpNSC) in the treatment of Parkinson’s disease (PD). Clearance for the trial came the Therapeutics Goods Administration (TGA) of Australia. The trial will test…
A novel physiological role for mitochondria with implications in the study of age-related diseases such as Parkinson’s has been described. Researchers found that mitochondrial dysfunction in proliferating human cells induces senescence growth arrest and causes cells to secrete distinct secretory phenotypes. The research paper, titled “Mitochondrial Dysfunction Induces Senescence with a Distinct…
Researchers at the Department of Neurological Surgery at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center recently received a $1 million grant to investigate the effectiveness of a diabetes drug for treating Parkinson’s disease. According to a press release from the…
A new study links a pesticide used prior to the early 1980s and milk consumed by adults during those years to substancia nigra neuronal death that is a hallmark of Parkinson’s disease. The research paper, titled “Midlife milk consumption and substantia nigra neuron density at death,” was published in Neurology, the journal…
Researchers at University of California, San Diego School of Medicine, are using a $375,000 grant from the Michael J. Fox Foundation (MJFF) to support work aiming to identify blood biomarkers that might finally lead to an early diagnosis of Parkinson’s disease. “One of the really unmet needs with Parkinson’s disease is the creation…
In a recent Medical Minute, a weekly health news feature from Penn State’s Milton S. Hershey Medical Center, Dr. James McInerney discusses developments in Parkinson’s disease research and the different approaches to symptom management, with special focus on deep brain stimulation (DBS). Parkinson’s disease (PD) is a progressive and…
Researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have uncovered a key protein, p53, as the key factor underlying the conversion from one cell type to another, such as skin cells to dopamine neurons. The research, which might have profound implications in the treatment…
In a recent study in the journal PLOS ONE, researchers from the Thomas Jefferson University demonstrate a way of helping the brain produce more of its own GM1 ganglioside, a molecule that has shown promise in relieving Parkinson’s symptoms and slowing disease progression. Numerous preclinical studies have shown that…
Recent Posts
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s
- Low muscle mass is more common in early-stage Parkinson’s disease
- Guest Voice: What de facto parenting can teach us about Parkinson’s
- Parkinson’s advocates urge implementation of new federal plan